Fusion protein · Antagonist of CD47 · developed by ALX Oncology
Evorpacept is a fusion protein made of a high-affinity CD47 blocker, a variant of SIRPa, linked to an inactive immunoglobulin Fc region. It binds CD47 on tumor cells, blocking its interaction with SIRPa on phagocytic cells, which promotes macrophage phagocytosis of tumor cells and activates anti-tumor T-cell responses. It is studied in head and neck, gastric, ovarian and breast cancers.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05002127 | Phase 2/3 | Gastric Cancer | Active not recruiting | ALXO |
| NCT05467670 | Phase 2 | Ovarian Cancer | Active not recruiting | ALXO |
| NCT05868226 | Phase 1/2 | HER2-positive Breast Cancer | Recruiting | JAZZ |
| NCT05027139 | Phase 1/2 | HER2-expressing Cancers | Completed | JAZZ |
| NCT04675294 | Phase 2 | Head and Neck Cancer | Active not recruiting | ALXO |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Gastric AdenocarcinomaGastric CancerGastroesophageal Junction AdenocarcinomaHead and Neck CancerHead and Neck Squamous Cell CarcinomaHER-2 Protein OverexpressionHER2 Mutation-Related TumorsHER2-negative Breast CancerHER2-positive Breast CancerHER2-positive Metastatic Breast CancerMetastaticMetastatic Breast CancerMetastatic CancerOvarian Cancer
Updated Oct 11, 2026. Something wrong or missing? Report it on the ALXO page.
See ALXO's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
ALXO catalysts and pipeline →